TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00520533

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric monoclonal antibody cG250
Description: First Cycle: cG250 10 mg/m² intravenous infusion, weekly for five weeks, followed by a two-week break. 1st \& 5th dose will be trace-labeled with a radioactive substance detectable on a PET scanner (124I-cG250).~Second cycle (investigator discretion): cG250 10 mg/m² intravenous infusion, weekly for four weeks followed by a two-week break. No 124I-cG250 will be used in the 2nd cycle.~Up to 2 cycles available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate
Description: First Cycle: Sunitinib 50 mg orally daily for 4 weeks (starts 8th day of 1st treatment cycle), followed by a two-week period off sunitinib.~Second cycle (investigator discretion): Sunitinib 50 mg orally daily for 4 weeks (starts on 1st day of 2nd treatment cycle), followed by a two-week period off sunitinib.~Up to 2 cycles available on-study.
Study: NCT00823069

Intervention type: DEVICE
Group type: OTHER
Intervention: Perlane and Perlane-L
Description: This is a split face design and each subject received both Perlane-L and Perlane. Treatments were blinded, randomized, and successive.
Study: NCT04046510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocytocin
Description: Administration of lower doses of Ocytocin in bolus and continuous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocytocin
Description: Administration of lower doses of Ocytocin in bolus and continuous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocytocin
Description: Administration of lower doses of Ocytocin in bolus and continuous infusion
Study: NCT02164331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JNC guideline training
Description: Providers will receive a series of trainings on what the JNC guidelines for treating uncontrolled hypertensives are and strategies for meeting those guidelines.
Study: NCT03668847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM-CHOC-PEN
Description: DM-CHOC-PEN administration by IV infusion
Study: NCT01901601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LALAK
Description: 1. A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~2. The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IEK
Description: 1. A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~2. In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retrobulbar Block or General Anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retrobulbar Block or General Anesthesia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optical coherence tomography (OCT)
Description: OCT will be used to guide the depth of the graft and donor dissections. The OCT systems to be used in this study will be the RTVue (Optovue, Inc., Fremont, CA) or the Visante (Carl Zeiss Meditec, Inc., Dublin, CA). Both are FDA-approved for the mapping of corneal thickness.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Anesthesia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: femtosecond laser
Description: The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: femtosecond laser
Description: The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
Study: NCT03081390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin conductance & cold pressor test
Description: Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation testing
Description: At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation testing
Description: At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques.
Study: NCT02065375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Ophthalmic Suspension 1.0%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Opthalmic Suspension 0.5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02838914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation (RFCA)
Description: Patients undergo radiofrequency ablation (RFCA)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation (RFCA)
Description: Patients undergo radiofrequency ablation (RFCA)
Study: NCT02040857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK 4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: Endocrine Therapy
Study: NCT03081390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation testing
Description: At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation testing
Description: At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques.
Study: NCT00091247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetracycline hydrochloride

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02418247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I131

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: I123
Study: NCT03648112

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention 1
Description: The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude oat flakes per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention 2
Description: The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted oat flakes per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention 3
Description: The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude barley flakes per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention 4
Description: The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted barley flakes per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: White toastbread (control) (dietary supplement) White toastbread was chosen because of its low fibre content. To achieve the same energy value (kcal) as 80 g cereal flakes the participants have to consume four slices of white toastbread.~The study participants receive recipes for breakfast for 21 days. The recipes imply four slices of white toastbread.
Study: NCT00526630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate (MPD)
Description: Participants will be given 1 mg/kg of MPD divided in three doses (at 8 am, 12 noon, and 4 pm). A four-week titration period will be used, using 0.25-mg/kg increments per week until achieving the weight-adjusted target dosage, which may range from five to eight 10-mg tablets per day. The maximum daily dose will be 80 mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be given placebo instead of active MPD.
Study: NCT02552628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic, Activa® PC on

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Medtronic, Activa® PC off
Study: NCT03577067

Intervention type: PROCEDURE
Intervention: Liver resection for primary and secondary disease
Description: Liver resection in parenchyma-sparing setting for primary and secondary disease
Study: NCT04123678

Intervention type: DEVICE
Intervention: Deep Ensemble for the Recognition of Malignancy (DERM)
Description: AI-based decision support tool
Study: NCT03631446

Intervention type: DRUG
Intervention: Sodium Picosulfate, Magnesium Oxide and Citric Acid
Description: Combination powder for oral solution
Study: NCT02697279

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Incision and Drainage.
Description: Control Group- Standard treatment of a simple cutaneous abscess with traditional I\&D technique with or without packing utilizing a standard I\&D kit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loop drainage
Description: Study Group- Treatment of a simple cutaneous abscess with the loop drainage technique utilizing an standard I\&D kit and the cuff of a sterile glove for a loop device.
Study: NCT01755442

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 151
Description: Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
Study: NCT00593567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gentamicin-collagen sponge
Description: Inserted daily into open ulcer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: 750mg oral levofloxacin daily
Study: NCT02244905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Deviance
Description: The recipients of the Positive Deviance intervention are the staff members of the three wards in the intervention arm, while the outcomes are measured among the patients receiving care in the three wards in the intervention arm. Key components of the intervention were invitation to participate voluntarily, open-ended dialogues with staff members to discover barriers and seek solutions to prevent HAI, discussion of outcomes, and encouragement to prioritize and implement the solutions generated.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard-of-Care Infection Control approach
Description: Standard-of-Care Infection Control approach

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard-of-Care Infection Control approach
Description: Standard-of-Care Infection Control approach
Study: NCT00590902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-774: erlotinib, TarcevaTM
Description: 150 mg, 100 mg and 25 mg tablets
Study: NCT01245465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Profermin
Description: Medical Food (food for special medical purposes)
Study: NCT00633815

Intervention type: OTHER
Intervention: Supine positioning
Description: Subjects underwent exercise testing on a stationary bicycle in the supine position

Intervention type: OTHER
Intervention: Supine positioning
Description: Subjects underwent exercise testing on a stationary bicycle in the supine position

Intervention type: OTHER
Intervention: Upright positioning
Description: Subjects underwent exercise testing on a stationary bicycle in the upright position

Intervention type: OTHER
Intervention: Upright positioning
Description: Subjects underwent exercise testing on a stationary bicycle in the upright position
Study: NCT02643576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: F&V Bonus
Description: To examine the independent effect of offering an incentive (i.e. bonus dollars for fruit and vegetable purchases) to SNAP-like benefits to encourage the purchase of more healthful foods
Study: NCT04342637

Intervention type: OTHER
Intervention: Practice details
Description: Physicians will report details of their endoscopy practice through answering the questions of the questionnaire
Study: NCT00119717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroFlo™ catheter
Description: 45 minute treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: ASA Guidelines
Study: NCT03131973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986195
Description: Specified dose on specified days
Study: NCT02643576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restriction
Description: To examine the independent effect of prohibiting the use of SNAP-like benefits to purchase foods high in discretionary calories (i.e.sugar-sweetened beverages, candy, or sweet baked goods) on food purchases and diet quality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bonus & Restriction
Description: To examine the joint effects of prohibiting the use of SNAP benefits to purchase foods high in discretionary calories and offering an incentive to encourage the purchase of more healthful foods
Study: NCT03713528

Intervention type: DRUG
Group type: OTHER
Intervention: Intraoperative Intraosseous Vancomycin
Description: After debridement and irrigation the interventional group will receive intraosseous vancomycin 500mg in 150ml of normal saline. This solution will be prepared by the hospital pharmacy and administered via an EZ-IO intraosseous cannula. 75ccs of the vancomycin solution will be injected as a bolus. Subsequent to this the remaining 75ccs will be placed in the distal femur just proximal to the femoral component evenly split between the medial and lateral femoral condyles in knees.
Study: NCT03131973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986195
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Specified dose on specified days
Study: NCT00501761

Intervention type: BEHAVIORAL
Intervention: Personalized Exercise Program
Description: Walking up to thirty minutes on most days of the week.
Study: NCT03131973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Specified dose on specified days
Study: NCT01339923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB + OMV NZ vaccine
Description: 3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB + OMV NZ vaccine
Description: 2 doses (3.5, 5 months of age) plus booster (11 months of age)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB + OMV NZ vaccine
Description: 2 doses (6, 8 months of age) plus booster (11 months of age)
Study: NCT01560325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-516 inj.
Description: CKD-516: 3.3\~13mg/m2/day
Study: NCT02352597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phytoestrogen
Description: 20mg of cimifuga racemosa from day 1- 12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol valerate
Description: 2mg from cycle day 7 to day 11

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: 50 mg orally every 8 hours started from cycle day 3 for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: 50 mg orally every 8 hours started from cycle day 3 for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: 50 mg orally every 8 hours started from cycle day 3 for 5 days
Study: NCT01920282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Study: NCT00501761

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires regarding physical activity, exercise, and quality of life.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires regarding physical activity, exercise, and quality of life.

Intervention type: BEHAVIORAL
Intervention: Suggested Exercise Program
Description: Exercise program performed over 7 days.
Study: NCT01694615

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprobe biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forceps Biopsy
Study: NCT00003213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 4 mg Dexamethasone in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 4 mg Dexamethasone in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron hydrochloride
Description: 1 mg Granisetron in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide hydrochloride
Description: 20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening)
Study: NCT00582036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Insulin
Description: Use of sliding scale insulin as per Appendix 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deployment of the MiniMed Paradigm monitoring device
Description: Automated insulin delivery system
Study: NCT02484820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone pessary
Description: Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
Study: NCT01339923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB + OMV NZ vaccine
Description: 2 doses 2 months apart
Study: NCT01920282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Modification
Study: NCT01454700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump therapy (CSII) plus continuous glucose monitoring (CGM)
Description: Randomization to 12 months with CSII plus CGM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiple daily insulin injections (MDI)
Description: Randomization12 months therapy with MDI
Study: NCT01290393

Intervention type: OTHER
Intervention: Data collection
Description: Data collection from hard copy interview forms routinely used by the Organization of Teratology Information Specialists (OTIS).

Intervention type: OTHER
Intervention: Data collection
Description: Data collection from hard copy interview forms routinely used by the Organization of Teratology Information Specialists (OTIS).
Study: NCT01153061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fistula closure with Gore Helex Septal Occluder
Description: The occluder will be released at the tracheoesophageal fistoulous traject through endoscopic procedures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gore Helex Septal Occluder
Description: Fistula closure with endoscopic release of occluder in the fistula traject.
Study: NCT00788190

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Distal Radius Fracture Reduction
Description: Surgical Intervention to Reduce Distal Radius Fracture

Intervention type: OTHER
Group type: OTHER
Intervention: Conservative Management
Description: Conservative management of Distal Radius Fractures
Study: NCT01305083

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Udenafil
Description: Placebo-control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Udenafil
Description: Placebo-control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02494128

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education in group leadership
Study: NCT01048333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Formoterol Turbuhaler 9 μg and Placebo Diskus